THE European Medicines Agency
has recommended approval of
Revestive (teduglutide) for the
treatment of adult patients with
short bowel syndrome.
Revestive is the first medical
treatment recommended for
approval in Europe for short bowel
syndrome (a condition in which
nutrients are not properly
absorbed, due to severe intestinal
disease or the surgical removal of a
large portion of the small
intestine).
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 25 Jun 12
Established in 2007, Pharmacy Daily is Australia's leading pharmacy industry publication, and is sent as a free subscription to people across the industry as a PDF newsletter every weekday.
To sign up for a free subscription, click on the button at right.
